Living past 100 is already possible, but scientists are now asking a much more ambitious question: can medicine deliberately slow the biology of aging enough to make exceptionally long lives more common? Experiments in animals suggest aging can be manipulated, and early human trials are beginning to target some of the cellular processes that drive it. But no treatment has yet been proven to make healthy humans live dramatically longer.
The oldest verified human lifespan remains 122 years, reached by Jeanne Calment. Crossing 100 is therefore not the biological mystery. The challenge is finding interventions that allow far more people to reach extreme ages without adding decades of frailty, cancer, dementia or cardiovascular disease.
Current research is attacking that problem from several directions, including drugs that alter nutrient-sensing pathways, therapies that remove damaged aging cells and experimental techniques that attempt to reset old cells toward a younger biological state.
Scientists have already extended lifespan in many animals
The strongest reason researchers take life-extension science seriously is that aging is not completely fixed in laboratory animals. Changes to diet, genes and specific biological pathways have repeatedly extended lifespan in organisms ranging from worms to mammals.
One of the most studied interventions is calorie restriction. Reducing calorie intake without causing malnutrition can extend lifespan in many animal species and influence pathways involved in metabolism, inflammation and cellular repair.
Scientists have spent years trying to reproduce some of those effects with drugs. Rapamycin is one of the leading candidates because it inhibits mTOR, a nutrient-sensing pathway that helps regulate cell growth and metabolism.
A 2025 meta-analysis covering 167 papers and eight vertebrate species found that rapamycin significantly extended lifespan across the animal studies examined. Its effect was comparable in magnitude to dietary restriction in the analysis, though results varied considerably between experiments.
That is powerful evidence that a drug can influence mammalian aging biology. It is not evidence that taking rapamycin will add decades to a human life.
Takeaway: Scientists can already extend lifespan in animals, proving that at least some mechanisms controlling aging are biologically adjustable.
Rapamycin has reached humans, but we still do not know if it extends human life
Rapamycin is especially interesting because researchers have moved beyond mice and begun testing mTOR-targeting drugs in people. The results suggest biological effects associated with aging, but human lifespan extension has not been demonstrated.
A systematic review of human trials found that rapamycin and related drugs improved some aging-associated measures involving immune, cardiovascular and skin function.
The review did not find consistent benefits across every body system, and some trials involving people with age-related diseases reported problems including higher infection rates and increases in cholesterol and triglycerides.
The practical challenge is enormous. Proving that a medicine makes humans live longer could require trials lasting decades.
Researchers therefore increasingly measure healthspan, biological-age markers and age-related diseases rather than waiting to see who lives to 110.
Rapamycin may eventually prove useful for specific aspects of aging. Right now, science cannot say it will make a healthy person live longer.
Takeaway: Rapamycin extends life in animals and affects aging-related biology in humans, but nobody has shown that it extends human lifespan.
Researchers are trying to remove the “zombie cells” that accumulate with age
Another major strategy targets senescent cells, often nicknamed zombie cells. These are damaged or stressed cells that stop dividing but do not disappear, allowing them to accumulate in tissues and release inflammatory chemicals that can affect nearby cells.
In mice, removing senescent cells can improve several age-related conditions and, in some experiments, extend healthy lifespan.
That led to the development of senolytics—drugs intended to selectively eliminate these cells.
Human testing has begun, but the results show how early the field remains. In one phase 2 trial, 60 postmenopausal women received the senolytic combination dasatinib and quercetin.
The treatment did not improve the trial’s primary measure of bone resorption across the full group. Researchers did see promising exploratory changes among women who started with a particularly high burden of senescent cells, suggesting such treatments may eventually need to be targeted to the right patients rather than given broadly.
A 2026 review noted that early human trials have produced biological signals but still lack clear evidence that senolytics meaningfully slow human aging.
Takeaway: Clearing senescent cells can rejuvenate animals, but researchers are still determining if the same strategy can meaningfully improve aging in people.
Scientists are trying something even more radical: making old cells younger
Perhaps the most ambitious strategy does not merely slow aging. It attempts to reverse some of the molecular changes that accumulate inside old cells by partially resetting their biological programming.
The approach grew out of the discovery that a combination of genes known as Yamanaka factors can turn adult cells back into an embryonic-like state.
Full reprogramming would be dangerous inside the body because cells could lose their identity or form tumors. Researchers therefore developed partial reprogramming, exposing cells to the factors only briefly in an attempt to erase some signs of aging without completely resetting what type of cell they are.
Experiments in old mice have produced striking results. Partial reprogramming has improved molecular markers of aging in several tissues and restored more youthful characteristics in parts of the aging brain. One study found increased production of neuronal precursor cells in aged mice following partial reprogramming.
Longer-term mouse experiments have also reported younger epigenetic profiles and improvements in age-associated tissue changes.
The major obstacle is safety. Researchers still need reliable ways to control exactly which cells are reprogrammed, for how long and how strongly.
Related: 6 Longevity Habits That Matter More Than Genetics
Save this article
Enter your email address and we'll send it straight to your inbox.
Takeaway: Scientists can make some old mouse tissues behave more youthfully, but safely performing controlled cellular reprogramming throughout a human body remains experimental.
Even familiar medicines are being investigated as longevity drugs
Not every candidate comes from futuristic biotechnology. Researchers are also investigating medicines already used for diabetes and other diseases because some influence the same metabolic pathways connected with aging.
Metformin has received enormous attention because observational studies have linked it with lower rates of several age-associated conditions in people with diabetes, while laboratory experiments suggest it affects pathways involving AMPK, mTOR, inflammation and cellular repair.
A 2026 review described considerable biological evidence supporting metformin as a potential geroprotective drug, but researchers still lack proof that it extends the lifespan of healthy humans.
GLP-1 drugs have now joined the conversation. In 2026, researchers reported that semaglutide treatment begun late in life extended median lifespan in female mice while producing some effects resembling calorie restriction.
That does not mean Ozempic or Wegovy should be viewed as human longevity drugs. It shows how treatments developed for metabolic disease may reveal pathways researchers can use to study aging itself.
Takeaway: Several existing medicines influence aging-related pathways, but none has yet been proven to extend the lifespan of healthy people.
The biggest goal may be healthspan, not reaching 150
Adding years means little if those years are dominated by disability and disease. Much of modern longevity science therefore focuses on healthspan: extending the period of life during which people remain physically and cognitively healthy.
A therapy that delayed heart disease, cancer, frailty and dementia simultaneously could have a profound impact even if it added only a modest number of years to maximum lifespan.
This is one reason researchers want to target aging biology itself rather than treating each disease separately after it appears.
Aging influences many chronic diseases through overlapping processes including inflammation, cellular senescence, mitochondrial dysfunction, genomic instability and declining tissue repair.
If scientists can slow those underlying processes, one intervention could theoretically delay multiple diseases at once.
That outcome may arrive much earlier than dramatic human life extension.
Takeaway: The most realistic near-term achievement is probably helping people stay healthy for longer, not creating generations of 150-year-olds.
There may still be biological limits we do not know how to overcome
Even if scientists solve several mechanisms of aging, the human body accumulates many kinds of damage simultaneously. Fixing one pathway may simply leave another as the new limiting factor.
A demographic analysis argued that dramatic life extension this century remains implausible without enormous reductions in mortality across nearly every major cause of death.
For average life expectancy to approach 110, survival into extreme old age would have to become routine rather than exceptional. That would require medicine to prevent or delay many different diseases at the same time.
Genomic damage may present another barrier. A 2026 study explored how mutations accumulated in ordinary body cells could eventually impose limits even if other drivers of aging were reduced.
That does not prove 122 years is a hard biological ceiling. It shows why extending maximum human lifespan is far more difficult than extending lifespan in a short-lived laboratory animal.
Takeaway: Human aging has many overlapping causes, so dramatically extending maximum lifespan may require repairing several types of biological damage at once.
So how close are we to extending human life beyond 100?
We are already good enough at medicine and public health that growing numbers of people reach 100 naturally. What scientists have not yet achieved is a treatment that reliably pushes healthy human lifespan beyond its current limits.
The field is much further along than it was a generation ago. Researchers can manipulate aging pathways, clear senescent cells, alter biological-age markers and partially rejuvenate tissues in animals. Human trials are now testing several therapies inspired by those discoveries.
But there is still a large gap between making an old mouse healthier and making a human live to 120.
No drug, supplement or genetic intervention has been proven to slow human aging enough to deliver dramatic lifespan extension. No partial-reprogramming therapy has been demonstrated to safely rejuvenate an entire human body, and no clinical trial has shown that senolytics or rapamycin allow healthy people to outlive normal human limits.
The first major success may therefore look less spectacular than immortality. It could mean reaching 90 or 100 with the physical and cognitive function people currently associate with someone decades younger.
If researchers can do that reliably, pushing lifespan further may become the next question.
Question for you. If science could give you another 20 healthy years without significantly extending the frail years at the end of life, would you want them?
